Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder

Stock Information for Mobio Technologies Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Mobio Technologies Inc.

Optimi Health Appoints Melanie Pump to Board of Directors
Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Optimi Health to Present at the Sidoti Micro-Cap Conference on January 21-22, 2026

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.